Duke University School of Medicine, 20 Duke Medicine Circle, Durham, NC 27710, USA.
Emory University, 1365-C Clifton Rd NE, Atlanta, GA 30322, USA.
Cancer Treat Rev. 2017 Nov;60:109-119. doi: 10.1016/j.ctrv.2017.08.006. Epub 2017 Aug 31.
Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.
B 型 Raf 激酶（BRAF）的致癌突变发生在 7-10%的转移性结直肠癌（mCRC）中。尽管最近 mCRC 一般人群的生存率有所提高，但 BRAF 突变型 mCRC 患者对大多数系统治疗的反应仍然不佳，预后仍然较差。因此，迫切需要新的治疗策略来治疗 BRAF 突变型 mCRC 患者。这篇综述概述了 BRAF 突变型 CRC 的流行病学、分子发病机制、预后和治疗耐药机制。此外，这篇综述还强调了旨在提高疗效和改善预后的新的治疗策略。
